Relay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) is expected to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $5.53 million for the quarter.

Relay Therapeutics Price Performance

Shares of Relay Therapeutics stock opened at $3.92 on Monday. The firm’s fifty day simple moving average is $4.37 and its 200-day simple moving average is $5.61. The stock has a market capitalization of $656.13 million, a price-to-earnings ratio of -1.50 and a beta of 1.61. Relay Therapeutics has a 12 month low of $3.50 and a 12 month high of $11.02.

Insider Buying and Selling at Relay Therapeutics

In other news, insider Peter Rahmer sold 32,156 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $4.15, for a total transaction of $133,447.40. Following the transaction, the insider now directly owns 357,507 shares of the company’s stock, valued at $1,483,654.05. This represents a 8.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sanjiv Patel sold 100,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $5.00, for a total transaction of $500,000.00. Following the transaction, the chief executive officer now directly owns 574,548 shares in the company, valued at approximately $2,872,740. This trade represents a 14.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 570,152 shares of company stock valued at $2,491,157. 4.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

RLAY has been the topic of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price on shares of Relay Therapeutics in a report on Thursday, December 12th. Leerink Partners cut their target price on shares of Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, December 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Relay Therapeutics in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.